PF-06282999

DB11683InvestigationalSmall molecule

Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).

Mechanism: Pharmacologically active on Myeloperoxidase
Curator reviewed
Formula / weight: C₁₃H₁₂ClN₃O₃S · 325.77 g/mol (avg)
Code names: PF-06282999

Resolves to

Compound

UNIIYO3O4Q2NC8CAS1435467-37-0ChEMBLCHEMBL3633460PubChem71571306

Structure

InChIKeyICYNYWFGIDGBRD-UHFFFAOYSA-NSMILESCOC1=CC=C(Cl)C=C1C1=CC(=O)NC(=S)N1CC(N)=O

Targets

P05164MPOO75469NR1I2

What you can answer from here — as of July 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with PF-06282999, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account